Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerHeather A. Wakelee, Jonathan Spicer, Christophe Dooms et al.|New England Journal of Medicine|2023Cited by 1k
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al.|The Lancet|2024Cited by 233
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and ResectionCharlotte Billiet, Dirk De Ruysscher, Stéphanie Peeters et al.|Journal of Thoracic Oncology|2016Cited by 25